General
AstraZeneca teams up with Russia’s Sputnik V vaccine for COVID-19 trials
AstraZeneca will start clinical trials to test a combination of its experimental COVID-19 vaccine with Russia’s Sputnik V shot, in a bid to boost the efficacy of the British drugmaker’s vaccine.
Key points:
- Moscow is likely to see the move as a vote of confidence in Sputnik V
- AstraZeneca, once seen as a frontrunner, has an average efficacy rate of 70.4 per cent
- Sanofi and GlaxoSmithKline vaccine trials show insufficient immune response in older people
Trials will start by the end of the year, according to Russia’s sovereign wealth fund, which has funded Sputnik V. The vaccine trial was named after the Soviet-era satellite that triggered the space race.
AstraZeneca said in a statement it was considering how it could assess combinations of…
-
General19 hours agoEnvironment Bill passes Senate as Greens cut deal with Labor
-
General20 hours agoTroops critically injured in Washington shooting named as FBI launch terror probe
-
Business19 hours agoWhat Warren Buffett’s farewell letter means for Berkshire Hathaway investors
-
General18 hours agoCalls for states to change alcohol laws ahead of women’s ministers meeting